Savara IncNASDAQ:SVRA
- LAST PRICE4.4900
- TODAY'S CHANGE (%)-0.1500 (-3.2328%)
- Bid / Lots4.4200/ 1
- Ask / Lots4.9000/ 2
- Open / Previous Close4.6200 / 4.6400
- Day Range
- 52 Week Range
- Volume5,386,498
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SVRA |
|---|---|---|
| 09:32 ET | 174824 | 4.57 |
| 09:34 ET | 4157 | 4.63 |
| 09:36 ET | 1892 | 4.58 |
| 09:38 ET | 400 | 4.57 |
| 09:39 ET | 578 | 4.61 |
| 09:43 ET | 700 | 4.55 |
| 09:45 ET | 100 | 4.54 |
| 09:48 ET | 259 | 4.5484 |
| 09:50 ET | 1914 | 4.52 |
| 09:52 ET | 200 | 4.51 |
| 09:54 ET | 14913 | 4.505 |
| 09:56 ET | 1051 | 4.49 |
| 09:57 ET | 2023 | 4.47 |
| 09:59 ET | 401 | 4.4604 |
| 10:01 ET | 1400 | 4.5 |
| 10:03 ET | 242 | 4.505 |
| 10:06 ET | 952 | 4.49 |
| 10:08 ET | 200 | 4.485 |
| 10:10 ET | 1538 | 4.485 |
| 10:12 ET | 1062 | 4.465 |
| 10:15 ET | 11884 | 4.445 |
| 10:17 ET | 758 | 4.46 |
| 10:19 ET | 1273 | 4.48 |
| 10:21 ET | 2035 | 4.47 |
| 10:26 ET | 100 | 4.47 |
| 10:28 ET | 200 | 4.475 |
| 10:30 ET | 100 | 4.48 |
| 10:32 ET | 2246 | 4.475 |
| 10:33 ET | 1340 | 4.47 |
| 10:35 ET | 2300 | 4.49 |
| 10:37 ET | 600 | 4.49 |
| 10:39 ET | 7679 | 4.485 |
| 10:42 ET | 305 | 4.475 |
| 10:44 ET | 400 | 4.475 |
| 10:46 ET | 200 | 4.48 |
| 10:48 ET | 1190 | 4.48 |
| 10:50 ET | 300 | 4.475 |
| 10:51 ET | 2654 | 4.48 |
| 10:53 ET | 700 | 4.49 |
| 10:55 ET | 1800 | 4.49 |
| 10:57 ET | 836 | 4.49 |
| 11:00 ET | 400 | 4.5 |
| 11:02 ET | 300 | 4.5 |
| 11:04 ET | 1162 | 4.5 |
| 11:06 ET | 300 | 4.495 |
| 11:08 ET | 1148 | 4.5 |
| 11:09 ET | 1000 | 4.5 |
| 11:11 ET | 1200 | 4.475 |
| 11:13 ET | 400 | 4.475 |
| 11:15 ET | 800 | 4.48 |
| 11:18 ET | 800 | 4.46 |
| 11:20 ET | 1916 | 4.48 |
| 11:22 ET | 613 | 4.485 |
| 11:24 ET | 1000 | 4.475 |
| 11:26 ET | 400 | 4.475 |
| 11:27 ET | 500 | 4.475 |
| 11:29 ET | 700 | 4.465 |
| 11:31 ET | 1604 | 4.46 |
| 11:33 ET | 2140 | 4.46 |
| 11:36 ET | 800 | 4.465 |
| 11:38 ET | 1004 | 4.48 |
| 11:40 ET | 900 | 4.485 |
| 11:42 ET | 451 | 4.485 |
| 11:44 ET | 6400 | 4.495 |
| 11:45 ET | 200 | 4.5 |
| 11:47 ET | 2570 | 4.49 |
| 11:49 ET | 600 | 4.485 |
| 11:51 ET | 1001 | 4.485 |
| 11:54 ET | 2474 | 4.475 |
| 11:56 ET | 800 | 4.47 |
| 11:58 ET | 2101 | 4.47 |
| 12:00 ET | 200 | 4.475 |
| 12:02 ET | 1400 | 4.475 |
| 12:03 ET | 4721 | 4.49 |
| 12:05 ET | 1700 | 4.495 |
| 12:07 ET | 4598 | 4.495 |
| 12:09 ET | 31758 | 4.545 |
| 12:12 ET | 6765 | 4.565 |
| 12:14 ET | 8102 | 4.575 |
| 12:16 ET | 5255 | 4.57 |
| 12:18 ET | 2301 | 4.57 |
| 12:20 ET | 17501 | 4.565 |
| 12:21 ET | 41248 | 4.575 |
| 12:23 ET | 14739 | 4.6 |
| 12:25 ET | 12981 | 4.595 |
| 12:27 ET | 12640 | 4.605 |
| 12:30 ET | 595 | 4.605 |
| 12:32 ET | 14366 | 4.61 |
| 12:34 ET | 25492 | 4.62 |
| 12:36 ET | 500 | 4.615 |
| 12:38 ET | 44546 | 4.595 |
| 12:39 ET | 2197 | 4.595 |
| 12:41 ET | 1600 | 4.595 |
| 12:43 ET | 7790 | 4.555 |
| 12:45 ET | 3432 | 4.545 |
| 12:48 ET | 4482 | 4.53 |
| 12:50 ET | 400 | 4.525 |
| 12:52 ET | 5167 | 4.535 |
| 12:54 ET | 798 | 4.535 |
| 12:56 ET | 26221 | 4.53 |
| 12:57 ET | 5353 | 4.525 |
| 12:59 ET | 2109 | 4.54 |
| 01:01 ET | 779 | 4.54 |
| 01:03 ET | 22102 | 4.535 |
| 01:06 ET | 1650 | 4.535 |
| 01:08 ET | 2772 | 4.56 |
| 01:10 ET | 1000 | 4.56 |
| 01:12 ET | 3983 | 4.545 |
| 01:14 ET | 300 | 4.545 |
| 01:15 ET | 4104 | 4.55 |
| 01:17 ET | 1274 | 4.55 |
| 01:19 ET | 548 | 4.545 |
| 01:21 ET | 1411 | 4.55 |
| 01:24 ET | 6075 | 4.545 |
| 01:26 ET | 684 | 4.545 |
| 01:28 ET | 1667 | 4.535 |
| 01:30 ET | 1100 | 4.525 |
| 01:32 ET | 1005 | 4.525 |
| 01:33 ET | 2761 | 4.535 |
| 01:35 ET | 700 | 4.545 |
| 01:37 ET | 1600 | 4.555 |
| 01:39 ET | 1556 | 4.5547 |
| 01:42 ET | 1727 | 4.555 |
| 01:44 ET | 900 | 4.56 |
| 01:46 ET | 1158 | 4.56 |
| 01:48 ET | 1810 | 4.55 |
| 01:50 ET | 1951 | 4.545 |
| 01:51 ET | 1257 | 4.545 |
| 01:53 ET | 700 | 4.55 |
| 01:55 ET | 1741 | 4.55 |
| 01:57 ET | 327 | 4.55 |
| 02:00 ET | 2609 | 4.545 |
| 02:02 ET | 2221 | 4.55 |
| 02:04 ET | 686 | 4.55 |
| 02:06 ET | 2351 | 4.545 |
| 02:08 ET | 1636 | 4.555 |
| 02:09 ET | 1559 | 4.56 |
| 02:11 ET | 1257 | 4.56 |
| 02:13 ET | 1470 | 4.565 |
| 02:15 ET | 1100 | 4.57 |
| 02:18 ET | 3120 | 4.57 |
| 02:20 ET | 2090 | 4.565 |
| 02:22 ET | 3448 | 4.57 |
| 02:24 ET | 900 | 4.565 |
| 02:26 ET | 687 | 4.56 |
| 02:27 ET | 1193 | 4.56 |
| 02:29 ET | 2573 | 4.5475 |
| 02:31 ET | 1057 | 4.56 |
| 02:33 ET | 1391 | 4.56 |
| 02:36 ET | 1000 | 4.56 |
| 02:38 ET | 840 | 4.56 |
| 02:40 ET | 2561 | 4.565 |
| 02:42 ET | 1269 | 4.565 |
| 02:44 ET | 300 | 4.565 |
| 02:45 ET | 1967 | 4.565 |
| 02:47 ET | 1786 | 4.565 |
| 02:49 ET | 3656 | 4.575 |
| 02:51 ET | 5128 | 4.575 |
| 02:54 ET | 6714 | 4.59 |
| 02:56 ET | 1275 | 4.5975 |
| 02:58 ET | 2782 | 4.605 |
| 03:00 ET | 3711 | 4.6 |
| 03:02 ET | 3371 | 4.6 |
| 03:03 ET | 1658 | 4.6 |
| 03:05 ET | 47951 | 4.595 |
| 03:07 ET | 2416 | 4.61 |
| 03:09 ET | 1000 | 4.605 |
| 03:12 ET | 2250 | 4.605 |
| 03:14 ET | 3132 | 4.62 |
| 03:16 ET | 3987 | 4.62 |
| 03:18 ET | 930 | 4.615 |
| 03:20 ET | 2803 | 4.62 |
| 03:21 ET | 1230 | 4.62 |
| 03:23 ET | 1689 | 4.63 |
| 03:25 ET | 1878 | 4.63 |
| 03:27 ET | 6727 | 4.625 |
| 03:30 ET | 1610 | 4.625 |
| 03:32 ET | 4344 | 4.63 |
| 03:34 ET | 1586 | 4.625 |
| 03:36 ET | 1519 | 4.63 |
| 03:38 ET | 5180 | 4.625 |
| 03:39 ET | 4813 | 4.64 |
| 03:41 ET | 11994 | 4.615 |
| 03:43 ET | 22236 | 4.605 |
| 03:45 ET | 63634 | 4.59 |
| 03:48 ET | 55489 | 4.541 |
| 03:50 ET | 24359 | 4.525 |
| 03:52 ET | 39248 | 4.545 |
| 03:54 ET | 10331 | 4.54 |
| 03:56 ET | 54255 | 4.515 |
| 03:57 ET | 107292 | 4.475 |
| 03:59 ET | 3289065 | 4.49 |
Sep 9, 2024
DJ Savara Price Target Maintained With a $9.00/Share by JMP Securities, from 10:32AM ET on Monday Sep 09, 2024 by Dow Jones
10:32AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 8, 2024
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024, from 6:45AM ET on Sunday Sep 08, 2024 by Dow Jones
6:45AM ET on Sunday Sep 08, 2024 by Dow Jones
Sep 6, 2024
Savara Announces New Employment Inducement Grant, from 4:05PM ET on Friday Sep 06, 2024 by Dow Jones
4:05PM ET on Friday Sep 06, 2024 by Dow Jones
Sep 3, 2024
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 4:05PM ET on Tuesday Sep 03, 2024 by Dow Jones
4:05PM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Savara Inc | 739.1M | -10.4x | --- |
Annexon Inc | 742.7M | -5.8x | --- |
Replimune Group Inc | 745.4M | -3.3x | --- |
Scholar Rock Holding Corp | 751.5M | -4.2x | --- |
MBX Biosciences Inc | 718.3M | -15.2x | --- |
Astria Therapeutics Inc | 713.8M | -5.5x | --- |
Company Information
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Contact Information
- Headquarters
- 6836 BEE CAVE ROAD BUILDING 3, SUITE 201AUSTIN, TX, United States 78746
- Phone
- 512-614-1848
- Fax
- 858-552-0876
Executives
- Chairman of the Board, Chief Executive Officer
- Matthew Pauls
- Chief Financial and Administrative Officer, Secretary
- David Lowrance
- Chief Operating Officer
- Robert Lutz
- Chief Business Officer
- Anne Erickson
- Chief Medical Officer
- Raymond Pratt
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $739.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 164.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-0.43 |
Book Value | $1.02 |
P/E Ratio | -10.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
